A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey
dc.contributor.author | Yılmaz D. | |
dc.contributor.author | Üstündağ G. | |
dc.contributor.author | Büyükçam A. | |
dc.contributor.author | Salı E. | |
dc.contributor.author | Çelik Ü. | |
dc.contributor.author | Avcu G. | |
dc.contributor.author | Belet N. | |
dc.contributor.author | Çakmak Taşkın E. | |
dc.contributor.author | Öcal Demir S. | |
dc.contributor.author | Birbilen A.Z. | |
dc.contributor.author | Kılıç Ö. | |
dc.contributor.author | Metin Akcan Ö. | |
dc.contributor.author | Tekin Yılmaz A. | |
dc.contributor.author | Aldemir Kocabaş B. | |
dc.contributor.author | Hatipoğlu N. | |
dc.contributor.author | Karbuz A. | |
dc.contributor.author | Çakır D. | |
dc.contributor.author | Sütçü M. | |
dc.contributor.author | Aygün F.D. | |
dc.contributor.author | Çelik T. | |
dc.contributor.author | Bayturan Şen S. | |
dc.contributor.author | Dalgıç N. | |
dc.contributor.author | Ümit Z. | |
dc.contributor.author | Kara S.S. | |
dc.contributor.author | Karadağ Öncel E. | |
dc.contributor.author | Bolat A. | |
dc.contributor.author | Kılıç Çil M. | |
dc.contributor.author | Turan C. | |
dc.contributor.author | Çakıl Güzin A. | |
dc.contributor.author | Topal S. | |
dc.contributor.author | Esen Besli G. | |
dc.contributor.author | Doğan G. | |
dc.contributor.author | Şahin S. | |
dc.contributor.author | Akın F. | |
dc.contributor.author | Bildirici Y. | |
dc.contributor.author | Timurtaş Dayar G. | |
dc.contributor.author | Ergül Sarı E. | |
dc.contributor.author | Kızmaz İşançlı D. | |
dc.contributor.author | Kara M. | |
dc.contributor.author | Önal P. | |
dc.contributor.author | Aylaç H. | |
dc.contributor.author | Lüleci D. | |
dc.contributor.author | Yaşar B. | |
dc.contributor.author | Dede E. | |
dc.contributor.author | Çağlar A. | |
dc.contributor.author | Akova S. | |
dc.contributor.author | Afat Turgut E. | |
dc.contributor.author | Yazıcı Özkaya P. | |
dc.contributor.author | Kandemir Gülmez T. | |
dc.contributor.author | Ulusoy E. | |
dc.contributor.author | Duyu M. | |
dc.contributor.author | Kara Y. | |
dc.contributor.author | Çeliktaş H. | |
dc.contributor.author | Tekeli O. | |
dc.contributor.author | Çağlar F. | |
dc.contributor.author | Gül D. | |
dc.contributor.author | Oral Cebeci S. | |
dc.contributor.author | Battal F. | |
dc.contributor.author | Bal A. | |
dc.contributor.author | Aygün E. | |
dc.contributor.author | Uysalol M. | |
dc.contributor.author | Arslan G. | |
dc.contributor.author | Özkavaklı A. | |
dc.contributor.author | Kızıl M.C. | |
dc.contributor.author | Yazar A. | |
dc.contributor.author | Aygün F. | |
dc.contributor.author | Somer A. | |
dc.contributor.author | Kuyucu N. | |
dc.contributor.author | Dinleyici E.Ç. | |
dc.contributor.author | Kara A. | |
dc.date.accessioned | 2024-07-22T08:02:41Z | |
dc.date.available | 2024-07-22T08:02:41Z | |
dc.date.issued | 2023 | |
dc.description.abstract | This multi-center point prevalence study evaluated children who were diagnosed as having coronavirus disease 2019 (COVID-19). On February 2nd, 2022, inpatients and outpatients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were included in the study from 12 cities and 24 centers in Turkey. Of 8605 patients on February 2nd, 2022, in participating centers, 706 (8.2%) had COVID-19. The median age of the 706 patients was 92.50 months, 53.4% were female, and 76.7% were inpatients. The three most common symptoms of the patients with COVID-19 were fever (56.6%), cough (41.3%), and fatigue (27.5%). The three most common underlying chronic diseases (UCDs) were asthma (3.4%), neurologic disorders (3.3%), and obesity (2.6%). The SARS-CoV-2-related pneumoniae rate was 10.7%. The COVID-19 vaccination rate was 12.5% in all patients. Among patients aged over 12 years with access to the vaccine given by the Republic of Turkey Ministry of Health, the vaccination rate was 38.7%. Patients with UCDs presented with dyspnea and pneumoniae more frequently than those without UCDs (p < 0.001 for both). The rates of fever, diarrhea, and pneumoniae were higher in patients without COVID-19 vaccinations (p = 0.001, p = 0.012, and p = 0.027). Conclusion: To lessen the effects of the disease, all eligible children should receive the COVID-19 vaccine. The illness may specifically endanger children with UCDs. What is Known: • Children with COVID-19 mainly present with fever and cough, as in adults. • COVID-19 may specifically threaten children with underlying chronic diseases. What is New: • Children with obesity have a higher vaccination rate against COVID-19 than children without obesity. • Among unvaccinated children, fever and pneumoniae might be seen at a higher ratio than among vaccinated children. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | |
dc.identifier.DOI-ID | 10.1007/s00431-023-04982-6 | |
dc.identifier.issn | 03406199 | |
dc.identifier.uri | http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11961 | |
dc.language.iso | English | |
dc.publisher | Springer Science and Business Media Deutschland GmbH | |
dc.rights | All Open Access; Bronze Open Access | |
dc.subject | Adult | |
dc.subject | Aged | |
dc.subject | Child | |
dc.subject | Chronic Disease | |
dc.subject | Cough | |
dc.subject | COVID-19 | |
dc.subject | COVID-19 Vaccines | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Inpatients | |
dc.subject | Male | |
dc.subject | Obesity | |
dc.subject | Outpatients | |
dc.subject | Prevalence | |
dc.subject | SARS-CoV-2 | |
dc.subject | Turkey | |
dc.subject | antibiotic agent | |
dc.subject | C reactive protein | |
dc.subject | corticosteroid | |
dc.subject | D dimer | |
dc.subject | ferritin | |
dc.subject | low molecular weight heparin | |
dc.subject | SARS-CoV-2 vaccine | |
dc.subject | SARS-CoV-2 vaccine | |
dc.subject | absolute lymphocyte count | |
dc.subject | absolute neutrophil count | |
dc.subject | adolescent | |
dc.subject | adult | |
dc.subject | Article | |
dc.subject | artificial ventilation | |
dc.subject | asthma | |
dc.subject | blood cell count | |
dc.subject | child | |
dc.subject | chronic disease | |
dc.subject | clinical feature | |
dc.subject | comorbidity | |
dc.subject | congenital heart disease | |
dc.subject | controlled study | |
dc.subject | coronavirus disease 2019 | |
dc.subject | coughing | |
dc.subject | cross-sectional study | |
dc.subject | diabetes mellitus | |
dc.subject | diarrhea | |
dc.subject | dyspnea | |
dc.subject | emergency ward | |
dc.subject | fatigue | |
dc.subject | female | |
dc.subject | ferritin blood level | |
dc.subject | fever | |
dc.subject | follow up | |
dc.subject | headache | |
dc.subject | health care access | |
dc.subject | high flow nasal cannula therapy | |
dc.subject | hospital admission | |
dc.subject | hospital patient | |
dc.subject | human | |
dc.subject | human tissue | |
dc.subject | hypertension | |
dc.subject | laboratory test | |
dc.subject | leukocyte count | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | multicenter study | |
dc.subject | myalgia | |
dc.subject | nasopharyngeal swab | |
dc.subject | neurologic disease | |
dc.subject | obesity | |
dc.subject | outpatient | |
dc.subject | outpatient department | |
dc.subject | pediatric intensive care unit | |
dc.subject | platelet count | |
dc.subject | pneumonia | |
dc.subject | point prevalence | |
dc.subject | polymerase chain reaction | |
dc.subject | preschool child | |
dc.subject | prevalence | |
dc.subject | protein blood level | |
dc.subject | school child | |
dc.subject | sore throat | |
dc.subject | Turkey (republic) | |
dc.subject | vaccination | |
dc.subject | young adult | |
dc.subject | aged | |
dc.subject | clinical trial | |
dc.subject | coronavirus disease 2019 | |
dc.subject | Severe acute respiratory syndrome coronavirus 2 | |
dc.subject | turkey (bird) | |
dc.title | A snapshot of pediatric inpatients and outpatients with COVID-19: a point prevalence study from Turkey | |
dc.type | Article |